1Seidel C, Sunden A, Hjoreh M, et al. Serum Syndecan-l: a new independent prognostic marker in multiple myeloma. Blood, 2000, 95: 388-392.
2Iwasaki Y, Hamano T, Ogata A, et al. Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma. Br J Haematol, 2002, 116: 796-802.
3Munshi NC, Wilson C. Increased done marrow microvessel density in newly diagnosed multiple myeloma. Carries a poor prognosis. Semin Oncol, 2001, 28: 565-569.
4Riccardi A, Mora O, Bmgnatelli S, et al. Relevance of age on survival of 341 patients with multiple myeloma treated with conventional therapy: update result of the MM87 prospective randomized protocol. Br J Cancer,1998, 77: 485-491.
5Kaneko M, karma Y, Oshima K, et al. Simple prognostic model for patients with mutiple myeloma: a single-center study in Japan. Ann Hematol, 2002, 81:33-36.
6Seong C, Delasalle K, Hayes K, et al. Prognostic value of cytogenetics in multiple myeloma. BrJ Haenmtol, 1998,101:189-194.
7Drach J, Sehuster J, Nowotny H, et al. Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization.Cancer Res,1995,55: 3854-3859.
8Fonseca R, Hanington D, Oken MM, et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (deltal 13) in multiple myeloma: an eastern cooperative ontology group study. Cancer Res, 2002, 62: 715-720.
9Facon T, Avet-Loiseau H, Guillerm G , et al. Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy.Blood, 2001, 97: 1566-1571.
10Fassas All, Spencer T, Sawyer J, et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol, 2002, 118: 1041-1047.
8Bergsagel PL,Kuehl WM, Zhan F, et al. Cyclin D dysregulation.-an early and unifying pathogenic event in multiple myeloma. [J]. Blood, 2005,106 (1) : 296-303.
9Jakob C, Egerer K, Liebisch P, et al. Circulating proteasome levels are an Independent prognostic factor for survival in multiple myeloma[J~. Blood, 2007,109 (5) : 21002105.
10Kyle RA, Rajkumar SV. Multiple Myeloma[J]. Blood, 2008,111(6) 2962-2972.
